Graphical abstract from Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes, by Bailey, Flatt, and Conlon, licensed under CC BY 4.0 Subscribe by email to follow the accumulating evidence and observations that shape our view of health, obesity, and policy.
Jin-Xiong She, founder of Jinfiniti Precision Medicine, explains: Most people assume their NAD+ is fine until they test it
At age 20, plasma levels are approximately 200 ng/mL, but by age 60, they drop to roughly 80 ng/mL
A randomized, double-blind, placebo-controlled trial of moclobemide in patients with chronic fatigue syndrome
276 The integration of wearable technology and biofeedback systems can further optimize personalized rehabilitation